The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo

Cancer Investigation

Volumn 16, Issue 8, 1998, Pages 549-553

  Vogler, William R ^a,d   Liu, Jianguo ^b   Volpert, Olga ^b   Ades, Edwin W ^c   Bouck, Noel ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Atlanta Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; EDELFOSINE; POLYMACON;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031770976     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809032884     Document Type: Article

References (23)

1. Folkman J: Tumor angiogenesis. In: The Molecular Basis of Cancer, edited by J Mendelsohn, PM Howley, MA Israel, et al, New York, WB Saunders, 1995, pp 206-232.
2. Bouck N, Stellmach V, Hsu S: How tumors become angiogenic. Adv Cancer Res 68:135-174, 1996.
3. Volpert OV, Ward WF, Lingen MW, et al: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671-679, 1996.
4. Lingen MW, Polverini PJ, Bouck N: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74:376-483, 1996.
5. Bouck N: Understanding tumor angiogenesis. Contemp Oncol 4: 14-23, 1994.
6. Vogler WR, Berdel WE: Autologous bone marrow transplantation in acute leukemia with edelfosine purged marrow, In: Acute Leukemias IV (Prognostic Factors), edited by T Buchner et al, Berlin, Springer-Verlag, 1993, pp 669-674.
7. Munder PG, Modolell M, Bausert W, et al: Alkyllysophospholipids in cancer therapy, In: Augmenting Agents in Cancer Therapy, edited by EM Hersh, New York, Raven Press, 1981, pp 441-458.
8. Berdel WE, Schlehe H, Fink U, et al: Early tumor and leukemia response to alkyl-lysophospholipids in phase 1 study. Cancer 50: 2011-2015, 1982.
9. Vogler WR, Olson AC, Shoji M, et al: Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines, In: The Pharmacological Effect of Lipids III, edited by JJ Kabara. Galena, IL, American Oil Chemists Society (AOCS), Lauricidin, 1989, pp 314-329.
10. Zheng B, Oishi K, Shoji M, et al: Inhibition of protein kinase C (Na-K-ATPase) and sodium pump by synthetic phospholipid analogues. Cancer Res 150:3025-3031, 1990.
11. 2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K652, and its inhibition by alkyl-lysophospholipid. Cancer Res 43:2955-2961, 1983.
12. Ades EW, Candal FJ, Swerlick RA, et al: HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99:683-690, 1992.
13. 33. Cancer Chemother Pharmacol 34:175-178, 1994.
14. 3) on human umbilical vein or microvascular endothelium. Pathobiology 63:109-114, 1996.
15. Huang S, Xie K, Bucana CD, et al: Interleukin-10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2:1969-1979, 1996.
16. Tolsma SS, Volpert OV, Good DJ, et al: Small peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511, 1993.
17. Berdel WE, Bausert WR, Weltzien HU, et al: The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-lewis lung carcinoma. Eur J Cancer 16:1199-1204, 1980.
18. O'Reilly MS, Holmgren L, Shing Y, et al: Cell 79:315-328, 1994.
19. Soldi R, Sanavio F, Aglieta M, et al: Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125FAK) in human endothelial cells. Oncogene 13: 515-525, 1996.
20. Cohen RA, Gebbhardt BM, Bazan NG: A platelet-activating factor antagonist reduces corneal allograft inflamation and neovascularization. Curr Eye Res 13:139-144, 1994.
21. Andrade SP, Vieira LB, Bakhle YS, Piper PJ: Effect of platelet-activating factor and other vasoconstrictors on a model of angiogenesis in the mouse. Int J Exp Pathol 73:503-513, 1992.
22. Dobson DE, Kambe A, Block E, et al: 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes. Cell 61:223-230, 1990.
23. Wakamatsu K, Masaki T, Itoh F, et al: Isolation of fatty acid amide as an angiogenic principle from bovine mesentery. Biochem Biophys Res Commun 168:423-429, 1990.